Lenz Therapeutics has filed a notice of an exempt offering of securities to raise $83,500,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Lenz Therapeutics is raising $83,500,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Evert Schimmelpennink played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Lenz Therapeutics
LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision. Our lead program is an aceclidine based eye drop designed to restore the loss of near vision associated with presbyopia. Presbyopia impacts almost two billion people globally and more than 120 million people in the US. LENZ Therapeutics is headquartered in San Diego, California, and is backed by multiple blue-chip venture capital investors.
To learn more about Lenz Therapeutics, visit http://lenz-tx.com/
Contact:
Evert Schimmelpennink, President and Chief Executive Officer
619-890-5125
https://www.linkedin.com/in/eef-schimmelpennink-03b4a45/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.